Immunovant will not seek approval for MG therapy, despite hitting endpoints
Immunovant has decided not to seek regulatory approval for its myasthenia gravis (MG) therapy, batoclimab, despite the Phase III study …
Post
-
-
Evinova and QLHC agree to incorporate RPM solution in breast cancer therapy trial
Healthcare technology company Evinova has entered an agreement with Quantum Leap Healthcare Collaborative (QLHC) to incorporate its remote patient monitoring …
-
High menopausal symptom burden linked to increased dementia risk
According to the World Health Organization (WHO), more than 55 million people have dementia globally. Though the major risk factor …
-
Navigating the triple-negative breast cancer global clinical trial landscape in 2025
A new report from leading global contract research organization Novotech examines the triple-negative breast cancer global clinical trial landscape in …
-
Innovent & HUTCHMED seek approval of kidney cancer combo after Phase II/III trial
Chinese-based Innovent Biologics and HUTCHMED are eyeing approval for their cancer combination after a joint Phase II/III kidney cancer trial …
-
Biofrontera enrols all subjects in trial of topical gel for actinic keratoses
US-based biopharmaceutical company Biofrontera has finished enrolling subjects in its multicentre Phase III trial of Ameluz (aminolevulinic acid hydrochloride) topical …
-
Ocugen receives DSMB approval to continue dosing in Phase I trial of OCU200
US-based biotechnology company Ocugen has received approval from the Data and Safety Monitoring Board (DSMB) to begin dosing the second …
-
Avidity’s del-zota elicits 25% increase in dystrophin in DMD patients
Avidity Biosciences’ Phase I/II trial of ribonucleic acid (RNA) therapy, del-zota, has increased dystrophin in patients with Duchenne muscular dystrophy …
-
FDA removes hold on vTv’s cadisegliatin clinical programme for diabetes
The US Food and Drug Administration (FDA) has removed the clinical hold on vTv Therapeutics' cadisegliatin clinical programme, including the …
-
Orca Bio makes a splash as T-cell therapy cuts GvHD in blood cancer patients
Orca Bio’s T-cell immunotherapy candidate for blood cancers has more than doubled the number of patients surviving free of moderate-to-severe …
-
The future of eClinical technology interoperability: Have your say
Today’s clinical landscape is increasingly data-driven, and technology interoperability is critical for advancing research and improving outcomes. But what demands …
-
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase III
UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic …
-
SolasCure initiates Phase II trial of chronic wound treatment gel
UK biotechnology company SolasCure has commenced the randomised, controlled CLEANVLU2 Phase II trial of Aurase Wound Gel for chronic wound …
-
Enrolment concludes in Zealand’s Phase IIb obesity therapy trial
Zealand Pharma has concluded enrolment for its global, randomised Phase IIb ZUPREME-1 trial, assessing the long-acting amylin analogue, petrelintide, in …
-
Investigating key strategies for optimising clinical trial supply chains in 2025
As the clinical trial landscape evolves with a growing demand for efficiency, flexibility, and innovation in 2025, experts will gather …
